TrialBreast cancer research and treatment2023

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.

Ailsa J Oswald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.